1. Japan Stocks

  2. •

    Industrials

  3. •

    Business Equipment & Supplies
Nichiban Co., Ltd.

Nichiban Co., Ltd.

4218.T
Nichiban Co., Ltd.JP flagTokyo Stock Exchange
1,897.00
JPY
-9.00
- -
38.28BMarket Cap
Nichiban Co., Ltd.
4218.T
(Tokyo Stock Exchange)

Recent

price

1,897.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
1,858.36
1,845.88
1,857.65
1,940.85
1,924.8
2,048.8
2,130.18
2,231.18
2,288.31
2,126.46
1,995.05
2,081.64
2,203.2
2,282.68
2,430.18
2,481.34
1,201.73
Revenue per Share
45.49
33.39
47.67
47.72
63.26
88.15
149.93
151.15
154.09
84.5
65.15
87.3
114.66
89
96.26
81.22
68.7
Basic EPS, GAAP
82.74
21.57
10.57
45.55
26.97
118.17
-76.77
-88.75
37.69
207.9
155.78
45.27
1.06
-28.11
113.36
16.13
- -
Free Cash Flow per Basic Share
11.96
11.96
12.01
11.97
12.01
15.97
21.96
35.95
39.91
37.93
33.01
29.97
30.08
35.12
34.94
35.01
- -
Dividend per Share
939.29
960.81
996.57
1,032.35
1,067.39
1,139.6
1,267.64
1,382.89
1,497.05
1,543.58
1,575.77
1,632.53
1,720.49
1,787.01
1,863.83
1,911.03
1,811.44
Book Value per Share
1,131.63
1,151.53
1,184.93
1,222.65
1,289.87
1,344.38
1,469.63
1,593.54
1,744.38
1,773.2
1,791.5
1,818.91
1,903.81
1,983.48
2,090.2
2,153.85
2,021.34
Tangible Book Value per Share
21
21
21
21
21
21
21
21
21
21
21
21
21
21
20
20
20
Basic Weighted Avg Shares
38,521
38,260
38,502
40,225
39,892
42,461
44,145
46,234
47,417
44,063
41,340
43,134
45,560
46,859
49,457
50,470
24,401
Sales/Revenue/Turnover
5.1
4.17
4.62
4.45
5.42
7.92
9.19
9.56
7.77
6.75
4.84
5.68
3.53
4.42
5.23
4.5
6.33
Operating Margin (%)
1,736
1,859
1,741
1,787
1,385
1,603
1,792
1,960
2,327
2,352
2,342
2,545
2,757
2,795
3,145
2,843
- -
Depreciation Expense
943
692
988
989
1,311
1,827
3,107
3,132
3,193
1,751
1,350
1,809
2,371
1,827
1,959
1,652
1,395
Net Income, GAAP
37.38
54.14
38.21
43.2
39.62
34.27
26.4
28.62
29.85
29.55
28.95
29.32
30.87
19.58
25.42
22.21
14.67
Effective Tax Rate (%)
2.45
1.81
2.57
2.46
3.29
4.3
7.04
6.77
6.73
3.97
3.27
4.19
5.2
3.9
3.96
3.27
5.72
Profit Margin (%)
17,137
14,959
16,608
17,227
17,751
18,160
16,050
13,730
14,968
19,246
19,575
19,543
20,095
21,759
22,716
21,984
22,670
Working Capital
2,481
423
2,502
2,507
2,438
2,326
2,251
2,170
137
2,104
2,069
2,094
2,090
2,082
2,080
108
2,000
LT Debt
23,527
23,949
24,791
25,547
26,884
28,138
30,764
33,315
36,479
37,216
38,076
38,959
40,602
41,702
43,186
44,324
41,847
Total Equity
4.69
2.74
4.01
3.59
4.45
7.14
9.1
8.97
6.81
5.31
3.54
4.17
2.59
3.82
4.29
3.81
3.03
Return on Invested Capital (%)
4.48
3.2
4.42
4.26
5.46
7.25
11.39
10.57
10.01
5.26
3.97
5.12
6.45
4.85
5.04
4.16
3.71
Return on Capital (%)
4.93
3.51
4.87
4.7
6.03
7.99
12.46
11.4
10.7
5.56
4.18
5.44
6.83
5.06
5.25
4.3
3.87
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
52
- -
- -
LT Borrowings
2,000
- -
2,000
LT Finance Leases
82
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
- -
20
Market Capitalization
40,894
39,046
38,782

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
38,639
- -
38,335
Cash, Cash Equivalents & STI
13,405
- -
14,016
Accounts Receivable, Net
9,649
- -
8,685
Inventories
9,277
- -
9,626
Total Current Liabilities
16,880
- -
15,665
Payables & Accruals
- -
- -
- -
ST Debt
52
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.69%
3.09%
2.64%
Free Cash Flow
-334.23%
-695.39%
-85.78%
Net Income, GAAP
3.84%
6.74%
-15.67%
Sales/Revenue/Turnover
1.84%
4.08%
2.05%
Total Cash Common Dividend
9.99%
1.12%
0.14%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,916
11,542
13,046
11,355
46,859
2025
- -
- -
- -
- -
49,457
2026
- -
- -
- -
- -
50,470

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13.63
- -
- -
- -
89
2025
- -
- -
- -
- -
96.26
2026
- -
- -
- -
- -
81.22

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
35.12
2025
- -
- -
- -
- -
34.94
2026
- -
- -
- -
- -
35.01
Similar Companies
ktk Inc. (3035.T)
Naman In-Store (India) Ltd. (NAMAN.NS)
SZZT Electronics CO.,LTD (002197.SZ)
Kokuyo Camlin Limited (KOKUYOCMLN.BO)
Xerox Holdings Corporation (XER2.DE)
Doms Industries Limited (DOMS.NS)
Business
Nichiban Co., Ltd. manufactures and sells adhesive tapes, medical products, and related adhesives primarily in Japan, Asia, and Europe. Founded in January 1918 and headquartered in Tokyo, Japan, the company offers a broad portfolio of products including medical tapes such as surgical tapes, wound care dressing tapes like CARELEAVES, post-operative care tapes, cornea protection tapes, hemostatic bandages, and first-aid bandages; sports medical products comprising battlewin taping tapes, kinesiology tapes, underwraps, scissors, and bags; healthcare items like anti-inflammatory patches, pain relief plasters such as ROIHI-TSUBOKO, foot care and corn plasters like SPEEL-KO, and waterproof films; industrial tapes for packaging, carton sealing, agriculture, automotive, construction, electronics, and machinery applications including masking tapes, PVC tapes, and cloth adhesive tapes; and stationery and office supplies such as CELLOTAPE cellulose tapes, double-sided tapes, adhesive transfer tapes, book binding tapes, and bag sealers. The company operates through segments including healthcare for general consumers and professionals, medical products for hospitals, office and home stationery, industrial applications, and overseas development via affiliates like Union Thai Nichiban Co., Ltd. in Thailand, exporting to approximately 50 countries with consolidated sales of 49.4 billion yen as of fiscal year 2025. In recent developments, Nichiban launched its new medium-term management plan "CREATION 2026" in April 2024, emphasizing innovation creation, globalization, and a new business portfolio to achieve the "NICHIBAN GROUP 2030 VISION" of global contributions; reported mixed first-half fiscal 2026 results with 1.6% net sales growth to support a full-year forecast of 4.1% sales increase and 16% operating profit rise; delayed its head office relocation to November 2025; and maintains a strong equity ratio of 64.1% while pursuing B2B and B2C expansions in hospital products and customer feedback-driven development.